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INTRODUCTION 
Non-small cell lung cancer 
Lung cancer (LC) with disappointing survival statistics represents the second most common 
forms of cancers in both men and women worldwide. The two main types of LC-s are small 
cell lung cancer (SCC) and non-small cell lung cancer (NSCLC) where the latter can be further 
classified into adeno (AC)-, squamous cell (SCC) - large cell (LCC) and various mixed types 
carcinomas accounting all together for approximately 85% of all LC cases. As the majority of 
patients are diagnosed at an advanced stage of the disease, the outcome is poor and the overall 
5-year survival rarely exceeds 15%. Naturally, earlier recognition would improve the outcome, 
but currently only a few treatment options are available to lung cancer sufferers that are largely 
based on identified driver mutations. Unfortunately, only a small percentage of NSCLC patients 
have such characteristic mutations therefore the majority cannot benefit from targeted therapy.  
NSCLC cases can be characterized with KRAS, EGFR mutations and ALK rearrangement, but 
those are not found in squamous cell carcinoma patients. Activating EGFR mutations usually 
occur within exon 18 and 21, which result in enhanced sensitivity for EGFR small molecule 
tyrosine kinases, such as gefitinib and erlotinib. Although KRAS mutation frequency is the 
highest in the Caucasian population, no treatment option is available yet in KRAS positive lung 
cancer patients. 
Anti-angiogenic therapy in lung cancer 
VEGF-A has been identified as a key regulator of both normal and pathological angiogenesis. 
In normal tissue during dormancy whereby angiogenesis is inhibited, levels of inhibitors and 
activators are equal, but alteration of pro-angiogenic or anti-angiogenic balance can facilitate 
tumor angiogenesis. This phenomenon is called “angiogenic switch” which favours abnormal 
angiogenesis. So the tumor can induce new blood vessel formation, but the newly formed 
network is often leaky, poorly differentiated and not hierarchic. Recognition that new blood 
vessel formation is important for tumor growth allowed the clinical application of anti-
angiogenic approach. The idea of anti-angiogenic therapy came from Judah Folkman from the 
early 70s. 
The first monoclonal antibody –bevacizumab- was approved against human VEGF-A the key 
regulator of angiogenesis. As VEGF-A promotes endothelial cell survival, migration, 
proliferation and vascular permeability it appears an ideal target to “starve” the tumor and lead 
to tumor regression. High VEGF-A expression in NSCLC tumors and its contribution in tumor 
progression makes it an appropriate candidate for therapy.   
Despite some success of bevacizumab mostly in combination therapy, patients mainly with 
squamous histology were excluded from treatment as increased risk of fatal side effects were 
observed. The reasons for serious haemorrhage are still unknown, but several ideas have come 
to light. For example, the two types of NSCLC-s are not only differ in genomic mutations, but 
AC and SCC possess different intratumoral blood vessel formations also and intratumoral 
vessels are less covered by pericytes in SCC than AC, leading to more vulnerable and fragile 
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vascular wall with increased necrosis in newly formed vessels in SCC. Solely blocking VEGF-
A simply cannot provide an overall therapeutic solution in NSCLCs, as alternative signaling 
pathways also play a significant role in the regulation of angiogenesis.  
Role of PPARgamma in carcinogenesis  
PPAR molecules are transcription factors of a nuclear hormone receptor superfamily. PPARs 
are important regulators of lipid storage and metabolism, but PPARs have been directly linked 
to tumorigenesis. As PPARgamma ligands can inhibit tumor cell proliferation, the involvement 
of PPARgamma ligands have been extensively studied regarding their potential antitumor 
capacity. PPARgamma activation by an agonist ligand can inhibit tumor growth, although the 
colon tumor size in APC mutant mice have been increased. One of the controversial regulators 
of VEGF-A is also the PPARgamma that has been reported to inhibit endothelial cell function 
and vasodilatation. According to the growing literature, PPARgamma can either activate or 
inhibit VEGF-A mediated endothelial cell response depending on the modulatory effect of the 
surrounding molecular microenvironment that expresses various additional regulators of 
angiogenesis.  
Wnt5a and angiogenesis 
The Wnt family of secreted glyco-lipo-proteins control a wide variety of cellular processes 
including cell fate specification, cell proliferation, cell polarity and cell migration therefore 
important in both fetal development and carcinogenesis. Their role in lung carcinogenesis has 
been also described, as enhanced activation of Wnt /beta-catenin pathway in Kras mutant mice 
lead to a more aggressive phenotype of the tumor. The Wnt signaling pathway, however, is not 
a single pathway. The most characterized Wnt pathway is the beta-catenin dependent canonical 
pathway. The Wnt signaling can also function in beta-catenin independent manner, called non-
canonical Wnt signaling, including the Ca2+ and the planar cell polarity (PCP) pathways. Wnt-
ligands, especially the non-canonical Wnt5a are also important regulators of endothelial cell 
division, survival and migration, consequently angiogenesis has also been proposed to be under 
Wnt control. Wnt5a expression has been investigated in 205 NSCLC samples and 
immunohistochemical analysis has revealed that Wnt5a expression significantly correlates with 
vascular mimicry. As canonical and non-canonical Wnt pathways are differentially active in 
AC and SCC, we considered the possibility that differences in the Wnt microenvironment can 
be partly responsible for variations in the tumor angiogenesis. Wnt5a was specifically selected 
as its up-regulation is characteristic to SCC tumors and its upregulation might also be 
responsible for alterations in blood vessel formation leading to serious side effects of anti-
angiogenic therapies.  
AIMS OF THE STUDY 
1. How VEGF-A changes during aging and lung carcinogenesis and what is its role in the 
altered angiogenesis? 
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2. Can canonical or non-canonical Wnt microenvironment affect PPARgamma 
expression? What molecules are responsible for the altered regulation? 
 
3. What are the functional consequences of altered Wnt microenvironment regarding 
endothelial cells? How Wnt molecules influence the angiogenesis of AC and SCC? 
MATERIALS AND METHODS 
Cell lines and primary cells 
Human foreskin fibroblast cell line (F11, System bioscience Mountain View, CA, USA) and 
human lung adenocarcinoma A549 (American Type Culture Collection, Rockville, MD) cell 
line were used for the experiments. VEGF overexpressing F11 cell line was generated in our 
laboratory. Normal primary human small airway epithelial cells (SAEC), normal human lung 
fibroblast (NHLF) and human microvascular lung endothelial cells (HMVEC-L) were 
purchased from Lonza, isolated from anonymous donors of different ages and sex.  
3D in vitro lung tissue aggregates 
To create a fully human 3D lung tissue model, SAEC, NHLF and HMVEC-L cells were used. 
All cells were cultured at 37°C and 5% CO2 in primary cell culturing media. After the cells 
reached 80% confluence, all types were sub-cultured and mixed [30% SAEC, 30% HMVEC-L 
and 40% NHLF together and dispensed onto a low-attachment 96-well U-bottom plate 
(Corning). Cells were centrifuged at 600g for 10 minutes and maintained at 37°C and 5% CO2 
in mixed SAGM:EGM-2:FGM-2 media during the experiments. Throughout the experiments, 
aggregates were treated with 10 mM LiCl (Sigma-Aldrich) for 48h and recombinant human 
Wnt5a and Wnt11 (R&D Systems) for 72h. 
Human samples  
Lung tissue samples (Supplementary table 1) were collected during lung resections at the 
Department of Surgery, University of Pécs, Hungary. The project was approved by the Ethical 
Committee of the University of Pécs. Patients had given written consent to provide samples for 
research purposes. All collected samples were treated anonymously. 
Animals 
For the experiments C57BL/6 and PPARgamma knock-out mice were used from both genders. 
Mice were kept under standardized conditions, where tap water and food was provided ad 
libitum. Animals were sacrificed at the age of 3.5 months. 
Gene expression studies 
Total RNA from cell cultures was extracted with MN NucleoSpin RNA isolation kit according 
to manufacturer’s protocol (Macherey-Nagel). The concentration of RNA samples was 
measured using NanoDrop (Thermo Scientific). 
Total RNA from human lung tissues were obtained using TRIzol reagent (Invitrogen). 1 µg 
RNA were digested with DNase (Sigma-Aldrich). cDNA was synthesized with high capacity 
RNA to cDNA kit (Life Technologies) using 1 μg of total RNA according to manufacturer’s 
recommendation. RT-PCR was performed using SensiFAST SYBR Green reagent (BioLine, 
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London, UK), Taqman Wnt array plate and Taqman microRNA assay. Amplifications were run 
on ABI StepOnePlus system. Gene expression were analyzed with StepOne software. 
Immunofluroescent and hematoxylin-eosin staining 
Mice were anaesthetized with sodium pentobarbital intraperitoneally and lungs were filled up 
with 1:1 ratio of PBS:cryostate embedding media (TissueTek Alphen aan den Rijn, Netherland), 
and frozen down at -80°C. The human samples were collected in PBS containing 1% of FBS 
and then were filled up with PBS:cryostate embedding media and kept at -80oC until processing.  
The 3D lung aggregates were carefully removed from the 96- well plates and embedded into 
TissueTek embedding media and immediately frozen down at -80°C. For histological 
observations, 8 µm thick cryostat sections were fixed with 4% PFA for 20 minutes. 
Fixed tissues sections were rehydrated and blocked for 20 minutes in 5% BSA in PBS. Primary 
antibodies were applied for 1 hour. The secondary antibodies were Alexa Fluor 488 or 555 
conjugated anti-mouse IgG antibodies (Life Technologies). The nuclei were counterstained 
with TO-PRO-3 (Life Technologies) and showed in blue as pseudo-color blue. Pictures were 
captured using Zeiss LSM 710 microscope equipped with analysis software. Images and 
fluorescent intensity were measured with Fiji software. Intensity of two groups was analyzed 
with the Student t test. 8 µm thick cryostat sections or Transwell inserts (Corning, New York, 
USA) were cut and stained in Mayer’s hematoxylin solution (Sigma-Aldrich, St. Louis, USA) 
for 10 minutes. Sections were washed in running tap water for 10 minutes, then differentiated 
with 0.25% acetic acid (Sigma Aldrich, St. Louis, USA) for 1 minute. After the differentiation 
step, slides were washed with tap water and stained in eosin solution for 2 minutes, then washed. 
Sections were mounted using Vectashield mounting medium (Vector Laboratories, 
Burlingame, USA). Images were taken using Nikon Eclipse Ti-U inverted microscope (Tokyo, 
Japan).  
PPRE reporter assay 
A549 cells were transfected with PPRE-luciferase reporter and PPRE control-luciferase 
reporter vectors using Lipofectamine 3000 (Thermo Fisher Scientific, Waltham, USA). 6*103 
cells were transfected with 100 ng of plasmid DNA mixed with 0.3 µl Lipofectamine 3000 and 
0.2 µl P3000 reagent (Thermo Fisher Scientific, Waltham, USA). After overnight incubation, 
cells were treated with LiCl at 10mM concentration for 24hours. Luciferase reporter, containing 
PPRE responsive element can be activated by PPAR activation, which catalyzes luciferin 
oxyluciferin transformation into luminescent signal. PPAR activation was measured using 
BrightGlo luciferase assay and detected by BioTek Synergy HT plate reader. Changes in PPAR 
activation were compared to PPRE control plasmid. RNA isolation was performed after 
24hours treatment. Gene expression was compared to non-treated cell cultures from three 
independent experiments.  For protein detection, transfected cells were treated with LiCl at 10 
mM concentration for 72 hours.  At the endpoint of the treatment; protein transport was blocked 
with 5mg/ml Brefeldin-A for 4 hours, as VEGF-A is a soluble factor. Immunfluorescent 
staining was performed using purified primary anti-human VEGF-A antibody, visualized by 
Alexa Fluor 488 conjugated anti-mouse secondary IgG antibody. Nuclei were stained by TO-
PRO3 and pseudo-colored for blue. Pictures were taken by Zeiss LSM 710. Images are 
representative from three different experiments.  
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PPARgamma agonist and antagonist treatment 
F11 cell line was cultured in 24-well plate and was treated with 10 μM rosiglitazone (RSG) and 
10 μM GW9662 (Sigma-Aldrich, St. Louis, USA) for 48h in the presence or absence of 
rhWnt5a (R&D Systems, Minneapolis, USA). VEGF-A mRNA level was determined using 
real-time quantitative PCR, while miR-27b expression was measured by Taqman MicroRNA 
Assay (Thermo Fisher Scientific, Waltham, USA).  
HMVEC-L Transwell migration assay 
HMVEC-L cells were seeded onto the Transwell insert (8 µm pore size, 6.5 mm diameter) 
(Corning Costar, Sigma Aldrich, St. Louis, USA) at the density of 2*104. To assess the effect 
of VEGF-A and Wnt5a, HMVEC-L were cultured in the presence or absence of elevated level 
of VEGF-A and recombinant human Wnt5a. To gain VEGF-A excess, F11-VEGFhigh cells 
were seeded into the well. F11-VEGFnormal cells were used as controls. After 24h, the inserts 
were stained with Hematoxylin-eosin (detailed protocol below) and pictures were taken using 
Nikon Eclipse Ti-U inverted microscope (Tokyo, Japan). 
Flow cytometry 
3D SAEC-F11 VEGFhigh- HMVEC-L and SAEC-F11-HMVEC-L lung aggregates were 
cultured for 72hours in the presence or absence of rhWnt5a. Aggregates were then dissociated 
with AccumaxTM (Sigma-Aldrich) solution and washed in PBS once. Single cell suspensions 
were incubated with Allophycocyanin (APC) conjugated anti-human CD105 (Clone 43A3, 
BioLegend) and Brilliant Violet 421 conjugated anti-human CD31 (Clone VM59, BioLegend) 
for 30 minutes at room temperature in dark. Cells were washed in PBS, fixed with 1% PFA and 
stored at 4°C in dark until FACS analysis. Labeled cells were analyzed with FACS Canto II 
flow cytometer (BD Immunocytometry Systems, Erembodegen, Belgium) with BD FACS 
DIVA software V6 and data were analyzed with FCS Express V3 software. 
Statistical analysis 
Statistical analysis was performed with SPSS version 20 software. Data are presented as mean 
± standard error of mean (SEM), and statistical analysis was performed using the independent 
sample t-test and one-way ANOVA with Bonferroni correction. p<0.05 was considered as 
significant.  
RESULTS 
VEGF-A expression in the lung 
Significantly increased VEGF-A expression was detected in old lung samples compared to 
young as controls as well as in both AC and SCC. PPARgamma levels were reduced in both 
tumor subtypes compared to normal, non-diseased lung controls. Quantitative analysis 
highlighted an existing difference in the two NSCLC subtypes, while lower PPARgamma 
mRNA levels characterized significantly higher VEGF-A expression in AC, higher 
PPARgamma and lower VEGF-A mRNA described SCC. 
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Wnt signaling in NSCLC 
As tumor progression has been associated with Wnt molecules, we studied canonical and non-
canonical Wnt signaling of AC and SCC samples. Elevated mRNA and protein level of non-
canonical Wnt5a was associated with SCC samples in contrast to AC patients.  
Connection between the canonical Wnt signaling and PPARgamma 
Investigating the role of Wnt and PPAR signaling pathway in VEGF-A production we studied 
the association between PPARgamma and Wnt pathway activation. PPRE plasmids containing 
specific PPAR binding site were used to determine PPAR activity. Treatment of A549 AC cell 
line with beta-catenin activator LiCl resulted in decreased promoter activity, while IWR-1 had 
no significant effect. Interestingly, VEGF-A mRNA level increased by both treatment, but LiCl 
led to increased protein level, while IWR-1 caused no significant change of VEGF-A protein 
expression. Wnt5a staining of the lungs of PPARgamma knock-out mice highlighted the 
importance of signaling activity, as the absence of PPARgamma did not lead to change in 
Wnt5a protein level demonstrating that Wnt5a is not under PPARgamma control. 
Wnt5a induces miR-27b a regulator of PPARgamma expression  
Based on the literature and experiments with the canonical Wnt pathway it appeared that only 
beta-catenin dependent signaling pathway activation is able to reduce PPARgamma expression 
and increase VEGF-A levels. It was not clear how SCC samples with high levels of the non-
canonical Wnt5a can trigger the same mechanism. miRNAs have been reported as regulators 
of angiogenesis and both miR-27b as well as miR-200b have been connected to Wnt, 
PPARgamma and VEGF-A pathways therefore we theorized that differences in miRNAs might 
explain the observed variations in blood vessel network formations of lung AC and SCC. To 
investigate, both miR-27b and miR-200b levels were measured in primary human AC and SCC 
samples. Significantly higher expression levels were determined for both miRNA in primary 
SCC tissues compared to AC. To test whether the different molecular microenvironment 
characterized by increased Wnt5a levels in SCC would explain variation in miRNA expression, 
3D lung aggregate cultures were exposed to non-canonical rhWnt5a. miR-27b expression was 
significantly increased by rhWnt5a treatment of the test tissue. In contrast, miR-200b levels 
were unaffected indicating a previously unidentified regulatory mechanism amongst signaling 
pathways of angiogenesis regulation. PPARgamma agonist and antagonist treatment along with 
rhWnt5a revealed that RSG can inhibit Wnt5a induced miR-27b increase, while antagonist 
GW9662 did not show the same effect. Interestingly, decreased VEGF-A expression level was 
detected in PPARgamma antagonist and Wnt5a combination treatment compared to antagonist 
alone. Such treatments led to the same patterns as in SCC cases.  
The role of Wnt5a in endothelial cell proliferation 
To be able to study the molecular regulation of VEGF-A induced endothelial cell functions, in 
vitro studies were performed using a three dimensional (3D) human lung aggregate model 
consisting of primary human small airway epithelial cells (SAEC), microvascular lung 
endothelial cells (HMVEC-L), and human fibroblasts (F). The 3D aggregate culture conditions 
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provided close to natural, yet defined, cellular environment for molecular studies. qRT-PCR 
analysis of tissue aggregates revealed highly similar expression levels of angiogenic stimulators 
including VEGF-A, IL-1beta and HIF-1alfa to primary human lungs indicating that the model 
is suitable to study pro- and/or anti-angiogenic mechanisms. As VEGF-A has previously been 
determined to stimulate endothelial cell functions, expression of CD105 marker, a 
transmembrane auxillary receptor for transforming growth factor-beta (TGF-beta) that is 
predominantly expressed on proliferating endothelial cells was also tested. The analysis of 
primary SCC and AC tissue samples showed significantly lower expression in SCC compared 
to AC tissue samples. Significantly lower PPARgamma and higher VEGF-A expression in both 
tumor tissue types is expected to generate enhanced angiogenesis, but analysis of CD105 
showed a reverse pattern. Contrary to our expectations decreased CD105 protein level was 
detected in CD31 positive endothelial cells of lungs in PPARgamma KO mice which is a similar 
pattern detected in human lung SCC samples. Based on the above results we hypothesized that 
elevated levels of VEGF-A alone are not sufficient to induce endothelial proliferation. To test 
whether rhWnt5a has a modulatory effect on pro-angiogenic mechanisms in a tumor-like 
VEGF-Ahigh environment, aggregates containing VEGF-Alow and VEGF-Ahigh fibroblasts were 
studied in the presence or absence of rhWnt5a. Flow cytometric analysis revealed that added 
rhWnt5a cannot block the expression of the endothelial cell proliferation marker CD105, 
indicating that CD105 marker is not under Wnt5a control.  
Cadherins 
Changes in the balance of different cadherin subtypes are a trademark of tumorigenesis. 
Treatment of recombinant Wnt5a resulted in decreased E-cadherin and increased N-cadherin 
mRNA levels. Investigating endothelial VE-cadherin in 3D lung aggregates we found that 
VEGF-A excess enhanced both N- and VE-cadherin, and that rhWnt5a had an additive effect 
and increased both mRNA levels even further.  
Wnt5a inhibits endothelial cell migration  
Our previous results indicate that Wnt5a is not a direct regulator of pro-angiogenic factor 
transcription, but it can alter VEGF-A mediated processes. To test whether rhWnt5a has a 
modulatory effect on pro-angiogenic mechanisms in a tumor-like VEGF-Ahigh environment, 
aggregates containing VEGF-Alow and VEGF-Ahigh fibroblasts were studied in the presence or 
absence of rhWnt5a. To detect the localization of endothelial cells in culture, tissue sections 
were prepared and stained for the CD31 endothelial cell marker. While in the VEGF-Alow 
microenvironment endothelial cells were evenly distributed in the tissue, in the presence of 
VEGF-Ahigh fibroblasts endothelial cells migrated towards the VEGF-A signal of fibroblasts -
that naturally provide the core of the 3D lung tissue aggregate co-culture- and formed a readily 
detectable endothelial cell stream. Added rhWnt5a inhibited endothelial cell migration towards 
the VEGF-Ahigh fibroblasts and the endothelial cells showed the same distribution pattern that 
was observed in the VEGF-Alow microenvironment. Transwell migration of HMVEC-L cells 
confirmed the regulatory role of Wnt5a. While endothelial cells migrated faster towards VEGF-
Ahigh microenvironment, added rWnt5a inhibited VEGF-A mediated migration.  
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SUMMARY 
1. How VEGF-A changes during aging and lung carcinogenesis and what is its role in the 
altered angiogenesis? 
VEGF-A mRNA level in aging lung is increased and the endothelial proliferation marker 
CD105 is also elevated. As NSCLC incidence is higher in the elderly it was not so surprising 
that the molecular pattern is similar in both NSCLC subtypes to lung samples of aging people. 
We have also reported that decreased PPARgamma expression is connected to VEGF-A 
increase. Our in vitro lung aggregates proved to be a suitable model system to investigate 
VEGF-A effects where we have shown that VEGF-A excess enhance endothelial proliferation 
and migration in 3D tissue aggregates. 
2. Can canonical or non-canonical Wnt microenvironment affect PPARgamma 
expression? What molecules are responsible for the altered regulation? 
Significantly reduced PPARgamma and increased VEGF-A levels in both AC and SCC samples 
were detected which result indicates increased angiogenesis. Different therapeutic response 
could not be explained by simply these two molecules. In our study, we described that 
PPARgamma mRNA and protein level can be reduced by activation of beta-catenin dependent 
Wnt pathway. Activation of canonical Wnt pathway also led to induced VEGF-A production 
via PPARgamma decrease. As the canonical Wnt pathway is more active in AC than SCC the 
above findings explained such an increase in VEGF-A in lung AC samples. The similarly high 
VEGF-A and reduced PPARgamma levels in SCC samples seem counter-intuitive as in SCC 
the non-canonical, beta-catenin independent Wnts play the dominant role. In non-canonical 
microenvironment, the inhibition of PPARgamma could be explained by Wnt5a induced 
upregulation of miR-27b that can inhibit PPARgamma.  
3. What are the functional consequences of altered Wnt microenvironment regarding 
endothelial cells? How Wnt molecules influence the angiogenesis of AC and SCC? 
Further investigation of Wnt5a revealed that Wnt5a cannot inhibit VEGF-A induced endothelial 
cell proliferation. Nevertheless, expression of cadherins that are important molecules in 
maintenance of cell-cell interaction and tissue integrity, changed after rhWnt5a treatment. 
Recombinant Wnt5a treatment of primary epithelial cell culture led to cadherin switch including 
E-cadherin decrease and N-cadherin increase. Using 3D lung aggregates as model systems we 
detected increased N- and endothelial VE-cadherin mRNA levels in the presence of Wnt5a. 
Functional tests also proved the inhibitory effect of Wnt5a on endothelial cell motility. Primary 
endothelial cells migrated faster in the presence of VEGF-Ahigh envorinment, while Wnt5a 
excess inhibited endothelial migration. These facts highlight the importance of the cancer type 
specific microenvironment on endothelial cells and partly explain the more fragile vascular wall 
in SCC making SCC patient more prone to haemorrhage upon anti-vascularization treatment.   
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